Profiling cell signaling pathway activity
Unravelling the molecular phenotype
Want to know more about OncoSignal?
We will get in touch with you as soon as possible.
We are excited to announce that the OncoSIGNal business has spun-out from Philips and continues as an independent company under the name InnoSIGN.
Philips Pathway Activity Profiling OncoSignal
A number of cell signal transduction pathways are known to play a role in the development of cancer. OncoSignal helps to gain insight into the functional activity of these underlying tumor driving signaling pathways. mRNA levels transcribed from direct target genes regulated by the pathway transcription factors are measured and translated into a quantitative pathway activity scores. The activity score of each pathway is reported on a scale from 0 to 100, resulting in a quantitative characterization of the cell molecular phenotype. OncoSignal can support drug development, patient stratification for clinical trials, and cancer research.
For examples on the use of OncoSignal, please request the OncoSignal application note via oncosignal@philips.com.
*For Research Use Only – not for use in diagnostic procedures.
OncoSignal products and services
Test for in-house use
OncoSignal Test
- ER, AR, PI3K, MAPK pathways
- Compatible with FFPE samples from human origin
- RT-qPCR testing plates including quality checks on sample input and correct plate filling
- Result overview in dedicated Pathway Activity Profiling Report
- Allows for in-house testing using standard laboratory equipment
- Developed under ISO13485
Service testing
OncoSignal Service
- ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFβ pathways
- Compatible with FFPE tissue samples and RNA extracted from cells and tissue of human origin
- Extensive quality checks on samples, laboratory process and results
- Result overview in dedicated Pathway Activity Profiling Report
- ISO13485 certified
Data analysis service
OncoSignal Data Service
- ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFβ, Wnt, JAK-STAT1/2*, JAK-STAT3*,
NF-КB* pathways
- Compatible with Affymetrix Microarray gene expression data and RNA sequencing data**
- Extensive quality checks on samples and results
- Result overview in dedicated Pathway Activity Profiling Report
* Under development.
** Please contact us for specific requirements.
** Please contact us for specific requirements.
OncoSignal is available for Research Use Only – not for use in diagnostic procedures.
Resources
For copies of one of the below mentioned publications and posters, please email us at oncosignal@philips.com.
Scientific publications
- Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium, Gynecologic Oncology, 2022
- Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function, Cancers, 2022
- Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube, AOGS, 2022
- Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma, Oral Oncology, 2021
- Androgen receptor pathway activity assay for sepsis diagnosis and prediction of favorable prognosis, Frontiers in Medicine, 2021
- Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma, Cancers, 2021
- Measuring host immune response status by simultaneous quantitative measurement of activity of signal transduction pathways that coordinate functional activity of immune cells from innate and adaptive immune system, BioRxiv, 2021
- Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1, Cancers, 2021
- Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade, Cancers, 2021
- Measurement of Activity of Developmental Signal Transduction Pathways to Quantify Stem Cell Pluripotency and Phenotypically Characterize Differentiated Cells, bioRxiv, 2021
- Heterogeneity in Signaling Pathway Activity within Primary and Between Primary and Metastatic Breast Cancer, Cancers 2021
- RNA Based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies, Frontiers in Genetics, 2021
- A molecular y for quantifying functional notch signaling pathway activity in human cancer, Cancers, 2020
- Measurement of cellular immune response to viral infection and vaccination, Frontiers in Immunology, 2020
- Signal transduction pathway activity in high-grade, serous ovarian carcinoma reveals a more favorable prognosis in tumors with low PI3K and high NF-КB pathway activity: A novel approach to a long-standing enigma, Cancers, 2020
- Oestrogen receptor pathway activity is associated with outcome in endometrial cancer, British Journal of Cancer, 2020
- Quantitative measurement of activity of JAK-STAT signaling pathways in blood samples and immune cells to predict innate and adaptive cellular immune response to viral infection and accelerate vaccine development, BioRxiv, 2020
- ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-freesurvival of metastatic patients under first-line tamoxifen, Cancers, 2020; Mar 27;12(4):802
- Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients, International Journal of Cancer, 2019; Jun 1;146(11):3196-3206. doi: 10.1002/ijc.32795. Epub 2019 Dec 12
- Estrogen receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer, Molecular Cancer Therapeutics, 2019; Feb;19(2):680-689
- Quantitative measurement of functional activity of the PI3K signaling pathway in Cancer; Cancers, 2019; Mar 1;11(3)
- Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types; Nature Scientific Reports, 2019; Feb 7;9(1):1603
- Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using forkhead box-o target gene expression in a knowledge-based computational model; The American Journal of Pathology, 2018; Sep;188(9):1956-1972
- Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell, Nature Scientific Reports, 2017; Sep 8;7(1):11030
- Knowledge-based computational models, Oncotarget, 2014; Jul 30;5(14):5196-7
- Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways, Cancer Research, 2014; Jun 1;74(11):2936-45
Posters
- Breast cancer IHC subtypes display heterogeneous and independent targetable signaling pathway activity profiles (AACR 2021)
- A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology (AACR 2021)
- Quantitative assessment of functional activity of multiple signaling pathways in recurrent breast cancer with low-intermediate 21 gene recurrence score (AMP 2020)
- Development of quantitative multi platform tests for easy readout of AR, ER, PI3K and MAPK pathway activity to unravel-pathophysiology across cancer and tissue types (AACR 2020)
- First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types (AACR 2020)
- EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets (online abstract, ASCO 2020)
- Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes (SABCS 2019)
- The MAPK pathway is variably active across breast cancer subtypes, and increased activity may be associated with hormonal therapy resistance (SABCS 2019)
- A test to quantify notch pathway activity in t cell acute lymphoblastic leukemia patients (ASH 2019)
- Fulvestrant resistance in an MCF-7 model for breast cancer is associated with complete loss of ER pathway activity and gain of MAPK-AP1 pathway activity (ANE 2019)
- Quantitative measurements of functional activity of the TGFβ and MAPK-AP1 pathways in colon cancer provides information on their role in cancer development and metastasis (ANE 2019)
- Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients (ESMO 2019)
- Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer (ESMO 2019)
- Signal transduction pathway activity in normal fallopian tube epithelium and high-grade serous carcinoma (ESGO 2019)
- Measuring functional PI3K and NFkB pathway activity to distinguish between short-term and long-term disease-free survivors of high grade serous ovarian cancer (ESGO 2019)
- Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases (ASCO 2019)
- Measuring the activity of multiple signal transduction pathways in cancer using RNA sequencing on cells and FFPE tissue (EACR Cancer Genomics 2019)
- ER pathway activity score as a predictive biomarker to improve stratification for neo-adjuvant endocrine therapy (ESMO Breast Congress 2019)
- Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblasts, and immune cell types: a new way forward to standardization of cell culture experiments (AACR 2019)
- Breast cancer induces a tolerogenic state of healthy activated CD4+ T-cells, characterized by reduced PI3K, NFκB, JAK-STAT, Notch, and increased TGFβ pathway activity (AACR 2019)
- Elucidating the role of functional signal transduction pathway activity in sensitivity and response of triple negative breast cancer PDxs to PI3K inhibition (SABCS 2018)
- Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort (SABCS 2018)
- Assays for measurement of functional signal transduction pathway activity in any cell or tissue sample (Keystone 2018)
- Signal transduction pathway activity before and after neoadjuvant treatment in esophageal cancer (ESMO 2018)
- Estrogen receptor pathway activity in endometrial carcinomas and its relation to tumor grade and disease related mortality (ESMO 2018)
- Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma (ESMO 2018)
- Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response (ENA 2018)
- Assays for measurement of functional signal transduction pathway activityin any cell or tissue sample (ENA 2018)
- Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma (EACR 2018)
- Robust measurement of signal transduction pathway activity in cancer using RNA sequencing on cells and FFPE tissue (AMPEu 2018)
- Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors (AACR 2018)
- Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types (AACR 2018)
- Measuring functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model (SABCS 2017)
- Assessing functional androgen receptor (AR) pathway activity using a computational model (ESMO 2017)
- Oncogenic signal transduction pathway activity in glioblastoma and relation to therapy response (EACR Cancer Genomics 2017)
- Analysis of active oncogenic signal transduction pathways in HGS ovarian cancer HH pathway activity associated with platin resistance (AMP 2017)
- Elucidating pediatric brain tumor pathophysiology by assessing signal transduction pathway activation (AACR 2017)
- Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways (AACR 2016)
- Prognosis within different breast cancer subtypes using functional activity of signaling pathways (AACR 2015)
- Assessing functional ER pathway activity using a computational pathway model (EACR 2014)
- Identifying tumor driving signaling pathways using computational pathway models (AACR 2013)
- Personalized cancer treatment selection using computational signaling pathway models (SABCS 2011)
Documentation
View the video to learn more about the OncoSignal technology.
View the video to learn more about next generation precision medicine.
Explore OncoSignal Test for in-house use
Measure the activity of the ER, AR, PI3K and MAPK signaling pathway in your molecular biology laboratory
This is what your colleagues say about OncoSignal
“Having information regarding signaling pathways that could underlie critical immunologic populations within the tumor microenvironment may be pivotal in understanding how drugs affect the cancer. I am very interested in new technologies that I can use to investigate signaling pathway activity in cancer cells and immune cells for my research in this area”.
Susan F. Slovin, MD, PhD
Professor of Medicine, Weill-Cornell Medical College
Attending Physician in the Genitourinary Oncology Service,
Sidney Kimmel Center for Prostate and Urologic Cancers,
Memorial Sloan-Kettering Cancer Center, New York, USAThis is what your colleagues say about OncoSignal
“High grade serous ovarian carcinoma is still a hard to treat cancer. During the last 20 years we have hardly seen an improvement of survival rates. Recently, we have demonstrated that OncoSignal helps to understand the molecular mechanisms driving high grade serous ovarian cancer in individual patients helping future selection of more effective personalized therapies with targeted drugs. We aim to start a prospective study to further investigate the potential of OncoSignal in patients with ovarian carcinoma”.
Jurgen M. Piek, MD, PhD
Gynaecological Oncologist, Department of Obstetrics and Gynecology,
Catharina Cancer Institute, Catharina Hospital, Eindhoven, The Netherlands
This is what your colleagues say about OncoSignal
"Nowadays, next-generation sequencing by using large panel is commonly recognized as a useful approach to improve cancer patient care. However, estimating the activity of specific pathways rather than single genes aberration may represent a more relevant approach to propose personalised cancer treatments by identifying the main driving mechanisms in each tumour. In this regard, Oncosignal represents a key innovation that can improve dramatically the capacity of molecular tumor board to recommend the right treatment for the right patient".
Prof. Antoine Italiano, MD, PhD
Head Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
Head Precision Medicine program, Gustave Roussy, Paris, France
This is what your colleagues say about OncoSignal
"OncoSignal Pathway Activity Profiling, a functional assay with a clear read out, has the potential to set a new standard for transforming precision oncology and may provide improved therapy selection options".
Anthony M. Magliocco, MD, PhD
Founder & CEO
Protean BioDiagnostics
Tampa/St. Petersburg, Florida, USA
Clinical Advisory Board
We are pleased to receive guidance and support by international experts:
- Carlos L. Arteaga, MD, UT Southwestern Medical Center, Dallas (USA)
- Jean-Yves Blay, MD, PhD, Centre Léon Bérard, Lyon (France)
- Fabien Calvo, MD, PhD, University of Paris Denis Diderot Medical School, Paris (France)
- Carla van Herpen, MD, PhD, Radboud University Medical Center, Nijmegen (NL)
- Hatim Husain, MD, University of California, San Diego (USA)
- Antoine Italiano, MD, PhD, Gustave Roussy, Villejuif (France)
- Cynthia Ma, MD, PhD, Washington University Medical School, St. Louis (USA)
- Christophe Massard, MD, PhD, Gustave Roussy, Villejuif (France)
- Mika Mustonen, PhD, Adj Prof, Southern Finland Regional Cancer Center, Helsinki University Hospital, Helsinki (Finland)
- Patrick Pauwels, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
- Mark Pegram, MD, Stanford Cancer Institute, Stanford (USA)
- Hans Prenen, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
- Dirk de Ruysscher, MD, PhD, Maastro, Maastricht University Medical Center, Maastricht (NL)
- Nabil F. Saba, MD, FACP, Emory University School of Medicine, Atlanta (USA)
- Cristina Saura, MD, PhD, Vall d'Hebron University Hospital, Barcelona (Spain)
- Henk Verheul, MD, PhD, Radboud University Medical Center, Nijmegen (NL)
- Susan F. Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York (USA)
- Karen Willard-Gallo, PhD, Institut Jules Bordet, Brussels (Belgium)
PACMAN study supported by EIT Health
Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)
The PACMAN study, in collaboration between Institute Gustave Roussy and Philips, will test how well the OncoSignal solution increases the effectiveness of new, personalized cancer therapy. Significant progress has been made with targeted drugs that block tumor-driving molecular pathways, but it is still difficult to predict how patients will respond. OncoSignal was designed to improve selection of optimal personalized therapy for individual patients and will contribute to disruption of cancer care by moving from treatment based on cancer type to tumor biology. Assessment of the functional molecular phenotype will provide improved therapy response prediction compared to DNA genotyping analysis alone. The project promises to improve clinical outcomes, especially for hard-to-treat cancers, reduce unnecessary side effects from ineffective therapies and save costs due to more effective (personalized) therapies.First results at ASCO and AACR 2020
• EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets, ASCO 2020• First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types, AACR 2020For more information, please visit www.eithealth.eu/pacman.
Contact us
Philips Molecular Pathway Diagnostics
High Tech Campus 11
5656 AE Eindhoven
The Netherlands
Phone: +31 40 2730155
Email: oncosignal@philips.com
You are about to visit a Philips global content page
You are about to visit the Philips USA website.
You are about to visit a Philips global content page
You are about to visit the Philips USA website.